echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > Pfizer and Flynn Pharmaceuticals accused of manipulation of prices of epilepsy drugs by British CMA

    Pfizer and Flynn Pharmaceuticals accused of manipulation of prices of epilepsy drugs by British CMA

    • Last Update: 2021-09-05
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    CompilationFan Dongdong

    A few days ago, the British Competition and Markets Authority (CMA) accused Pfizer and Flynn Pharmaceuticals of violating antitrust rules and increasing the prices of anti-epileptic treatments, resulting in them charging the British National Health Service (NHS) excessive treatment fees
    .

    CMA accused Pfizer and Flynn of deliberately increasing the sales price of phenytoin sodium capsules
    .
    According to the CMA report, in 2012, the two companies “de-branded” drugs sold under the Epnutin brand name


    .


    The CMA accused Pfizer and Flynn Pharmaceuticals of exploiting a loophole in curbing the price of drugs purchased by the NHS


    .


    CMA said that after the removal of the brand, Pfizer increased the price of such drugs by 780% to 1,600%
    .
    Pfizer subsequently provided the drug to Flynn Pharmaceuticals, and Flynn Pharmaceuticals continued to raise prices on the basis of Pfizer and sold it in the UK at a price of 2300% to 2600%


    .


    Pfizer and Flynn Pharmaceuticals were initially fined £84.
    2 million by the CMA for price increases in 2016, but the two companies refused to accept the judgment and subsequently appealed
    .
    In June 2018, the Competition Appeals Court upheld the CMA’s ruling on the market definition and monopoly status of Pfizer and Flynn, but rejected the CMA’s ruling that Pfizer and Flynn’s prices were illegally “abusing” of their dominant position


    .


    CMA Chief Executive Andrea Coscelli said in a statement, “There are approximately 48,000 epilepsy patients in the UK relying on this drug to prevent life-threatening seizures caused by epilepsy.
    Very important
    .
    Protecting these patients, the NHS and the taxpayers who fund them is the top priority of the CMA


    .


    According to the British "Guardian" report, currently Pfizer and Flynn Pharmaceuticals have the opportunity to respond to the CMA's interim investigation results before the regulators reconsider whether they violated the law


    .


    It is worth noting that in recent weeks, the CMA has imposed penalties on a series of similar violations of price increases, such as fines of US$260 million on pharmaceutical companies associated with Auden Mckenzie and Actavis UK, on ​​the grounds that the two companies have increased the number of companies in the UK.


    The price of hydrocortisone used by ten thousand people


    Reference source:

    1.


    2.


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.